When should a university student be allowed academic accommodation For ADHD? A position statement for a unified procedure for use in Brazil.
ADHD
academic accommodation
eligibility criteria
Journal
Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)
ISSN: 1809-452X
Titre abrégé: Braz J Psychiatry
Pays: Brazil
ID NLM: 100895975
Informations de publication
Date de publication:
01 May 2023
01 May 2023
Historique:
received:
10
12
2022
accepted:
10
04
2023
medline:
2
5
2023
pubmed:
2
5
2023
entrez:
1
5
2023
Statut:
aheadofprint
Résumé
To identify under what circumstances a university student should be allowed academic accommodation for ADHD. To frame an evidence-based policy for use in Brazil based on a worldwide experience. We reviewed the literature to acquire information on what documents are commonly required by disability services before accommodation for ADHD is made (including malingering detection). We scrutinized the eligibility criteria of the best universities worldwide. Renowned experts in the field and national stakeholders were consulted. We found no international standard for the assessment of students with ADHD who request academic accommodation. Even renowned institutions worldwide differ from one another in their approaches to academic accommodation on the grounds of ADHD. We propose a national unified set of criteria for Brazilian universities, which could generalize internationally. Rigorous assessment is paramount for aiding students with disabilities while preventing ineligible students gaining an unfair advantage. Higher education institutions nationwide and beyond may benefit from adopting a unified set of criteria for eligibility to ADHD accommodation programs.
Identifiants
pubmed: 37127329
doi: 10.47626/1516-4446-2022-2999
pmc: PMC10668313
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Escola Superior de Propaganda e Marketing
Pays : Brazil
Déclaration de conflit d'intérêts
Luis Augusto Rohde has received grant or research support from, served as a consultant to, and served on the speakers’ bureau of Aché, Bial, Medice, Novartis/Sandoz, Pfizer/Upjohn, and Shire/Takeda in the last three years. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by Dr Rohde have received unrestricted educational and research support from the following pharmaceutical companies in the last three years: Novartis/Sandoz and Shire/Takeda. Dr Rohde has received authorship royalties from Oxford Press and ArtMed. Dr. Hinshaw receives book royalties from Oxford University Press and St. Martin’s Press. The other authors report no conflicts of interest.
Références
J Atten Disord. 2008 Sep;12(2):156-61
pubmed: 18192625
J Atten Disord. 2019 Dec;23(14):1780-1791
pubmed: 25534434
Psychol Assess. 2017 Dec;29(12):1437-1446
pubmed: 29227125
Lancet. 2020 Feb 8;395(10222):450-462
pubmed: 31982036
J Atten Disord. 2014 Apr;18(3):186-201
pubmed: 22582347
J Clin Child Adolesc Psychol. 2021 Nov-Dec;50(6):828-843
pubmed: 33529049
Clin Neuropsychol. 2010 Oct;24(7):1204-37
pubmed: 20845231
J Atten Disord. 2022 Apr;26(6):893-901
pubmed: 34384265
Psychol Assess. 2019 Jun;31(6):793-804
pubmed: 30702310
Psychol Assess. 2019 Feb;31(2):265-270
pubmed: 30359048
J Atten Disord. 2015 Aug;19(8):655-65
pubmed: 24131894